183321-69-9 Usage
Description
Erlotinib Hydrochloride is a targeted therapy medication, specifically a tyrosine kinase inhibitor, derived from the class of drugs used to treat specific types of cancer. It functions by inhibiting the epidermal growth factor receptor (EGFR), a protein that plays a crucial role in the growth and spread of cancer cells. This inhibition helps to slow down or halt the progression of cancer, making it a significant pharmaceutical candidate in oncology.
Uses
Used in Oncology:
Erlotinib Hydrochloride is used as an anticancer agent for the treatment of non-small cell lung cancer and pancreatic cancer. It targets the EGFR protein, thereby inhibiting the growth and spread of cancer cells, which is instrumental in managing the progression of the disease.
Used in Combination Therapy:
Erlotinib Hydrochloride is often used in conjunction with other cancer treatments to enhance the overall therapeutic effect. Its role as a tyrosine kinase inhibitor complements other treatment modalities, potentially leading to better patient outcomes.
Used in Oral Medication:
Erlotinib Hydrochloride is typically administered orally in tablet form, providing a convenient and accessible method for patients to receive their medication.
Common side effects associated with the use of Erlotinib Hydrochloride include diarrhea, rash, loss of appetite, and fatigue, which are important considerations in patient management and treatment planning.
Check Digit Verification of cas no
The CAS Registry Mumber 183321-69-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,3,3,2 and 1 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 183321-69:
(8*1)+(7*8)+(6*3)+(5*3)+(4*2)+(3*1)+(2*6)+(1*9)=129
129 % 10 = 9
So 183321-69-9 is a valid CAS Registry Number.
183321-69-9Relevant articles and documents
Quinazoline derivatives
-
, (2008/06/13)
The invention relates to certain 4-(substitutedphenylamino)quinazoline derivatives of formula (I), their produgs and pharmaceutically acceptable salts wherein R1, R2, R3, R4, m and n are described in said formula. The compounds of formula (1), their produgs and pharmaceutically acceptable salts are useful for the treatment of hyperproliferative diseases.
